BindingDB logo
myBDB logout

55 articles for thisTarget


The following articles (labelled with PubMed ID or TBD) are for your review
PMIDDataArticle TitleOrganization
27939345 22 Influence of chain length on the activity of tripeptidomimetic antagonists for CXC chemokine receptor 4 (CXCR4).EBI University of Bergen
27576294 2 Synthesis and evaluation of 2,5 and 2,6 pyridine-based CXCR4 inhibitors.EBI Georgia State University
27434274 56 Structure-Activity Relationship and Signaling of New Chimeric CXCR4 Agonists.EBI Universit£ de Sherbrooke
27571038 18 Exploring the N-Terminal Region of C-X-C Motif Chemokine 12 (CXCL12): Identification of Plasma-Stable Cyclic Peptides As Novel, Potent C-X-C Chemokine Receptor Type 4 (CXCR4) Antagonists.EBI Second University of Naples
26509831 29 Anti-HIV Drug Discovery and Development: Current Innovations and Future Trends.EBI Shandong University
26974376 2 Discovery of non-peptide small molecular CXCR4 antagonists as anti-HIV agents: Recent advances and future opportunities.EBI Shandong University
26453409 2 Exploration of labeling by near infrared dyes of the polyproline linker for bivalent-type CXCR4 ligands.EBI Tokyo Medical and Dental University
26348881 54 Identification of Substituted Naphthotriazolediones as Novel Tryptophan 2,3-Dioxygenase (TDO) Inhibitors through Structure-Based Virtual Screening.EBI National Health Research Institutes
25935642 17 Discovery of novel N-aryl piperazine CXCR4 antagonists.EBI Emory Institute for Drug Development
26191361 6 Pyrazolo-Piperidines Exhibit Dual Inhibition of CCR5/CXCR4 HIV Entry and Reverse Transcriptase.EBI Emory University
25082513 30 Design, synthesis, and biological evaluation of scaffold-based tripeptidomimetic antagonists for CXC chemokine receptor 4 (CXCR4).EBI UiT The Arctic University of Norway
26042340 77 Development of novel CXC chemokine receptor 7 (CXCR7) ligands: selectivity switch from CXCR4 antagonists with a cyclic pentapeptide scaffold.EBI Kyoto University
24983484 11 Toward fluorescent probes for G-protein-coupled receptors (GPCRs).EBI Shandong University
23434419 13 Improved guanide compounds which bind the CXCR4 co-receptor and inhibit HIV-1 infection.EBI Montana State University
11128640 22 Pharmacophore identification of a specific CXCR4 inhibitor, T140, leads to development of effective anti-HIV agents with very high selectivity indexes.EBI Kyoto University
21381769 56 Macrocycles are great cycles: applications, opportunities, and challenges of synthetic macrocycles in drug discovery.EBI Universite£ de Sherbrooke
23043442 30 Rational design of conformationally constrained cyclopentapeptide antagonists for C-x-C chemokine receptor 4 (CXCR4).EBI University of Troms£
22931505 69 Chemokine receptor antagonists.EBI National Heart and Lung Institute
22909088 6 Noncyclam tetraamines inhibit CXC chemokine receptor type 4 and target glioma-initiating cells.EBI Universitat Ramon Llull
22352868 8 Structure-activity relationship study of a CXC chemokine receptor type 4 antagonist, FC131, using a series of alkene dipeptide isosteres.EBI Kyoto University
16821774 86 Design, synthesis, and biological evaluation of the combinatorial library with a new spirodiketopiperazine scaffold. Discovery of novel potent and selective low-molecular-weight CCR5 antagonists.EBI Ono Pharmaceutical Co., Ltd.
10508445 10 Synthesis and structure-activity relationships of phenylenebis(methylene)-linked bis-azamacrocycles that inhibit HIV-1 and HIV-2 replication by antagonism of the chemokine receptor CXCR4.EBI AnorMED Inc.
11459656 27 Development of specific CXCR4 inhibitors possessing high selectivity indexes as well as complete stability in serum based on an anti-HIV peptide T140.EBI Kyoto University
22365757 2 Molecular modeling study of cyclic pentapeptide CXCR4 antagonists: new insight into CXCR4-FC131 interactions.EBI PharmaDesign, Inc.
21905730 20 Design, synthesis, and functionalization of dimeric peptides targeting chemokine receptor CXCR4.EBI Technische Universit£t M£nchen
21658961 72 Discovery of 4-[4-({(3R)-1-butyl-3-[(R)-cyclohexyl(hydroxy)methyl]-2,5-dioxo-1,4,9-triazaspiro[5.5]undec-9-yl}methyl)phenoxy]benzoic acid hydrochloride: a highly potent orally available CCR5 selective antagonist.EBI Ono Pharmaceutical Co. Ltd
21105715 4 Dipyrimidine amines: a novel class of chemokine receptor type 4 antagonists with high specificity.EBI Emory University
21295470 27 Design of novel CXCR4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.EBI Genzyme Corp.
19451305 3 The novel CXCR4 antagonist KRH-3955 is an orally bioavailable and extremely potent inhibitor of human immunodeficiency virus type 1 infection: comparative studies with AMD3100.EBI National Institute of Infectious Diseases
21109432 22 Synthesis and SAR of novel CXCR4 antagonists that are potent inhibitors of T tropic (X4) HIV-1 replication.EBI Genzyme Corp
20728351 4 CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.EBI Tokyo Medical and Dental University
19949058 15 Blockade of X4-tropic HIV-1 cellular entry by GSK812397, a potent noncompetitive CXCR4 receptor antagonist.EBI GlaxoSmithKline Research and Development
20443225 3 Synthesis and SAR of novel isoquinoline CXCR4 antagonists with potent anti-HIV activity.EBI GlaxoSmithKline Research and Development
20297846 33 Discovery of novel small molecule orally bioavailable C-X-C chemokine receptor 4 antagonists that are potent inhibitors of T-tropic (X4) HIV-1 replication.EBI Genzyme Corp.
20207537 3 Novel N-substituted benzimidazole CXCR4 antagonists as potential anti-HIV agents.EBI GlaxoSmithKline Research and Development
19674898 31 Spiropiperidine CCR5 antagonists.EBI Roche Palo Alto LLC
20004096 49 Identification of a new class of small molecule C5a receptor antagonists.EBI Wyeth Research
19188071 2 64Cu-AMD3100--a novel imaging agent for targeting chemokine receptor CXCR4.EBI National Institute of Biomedical Imaging and Bioengineering
19053768 64 Orally bioavailable isothioureas block function of the chemokine receptor CXCR4 in vitro and in vivo.EBI Novartis Institutes for BioMedical Research
19014885 32 Discovery of a potent, selective and orally bioavailable 3,9-diazaspiro[5.5]undeca-2-one CCR5 antagonist.EBI Roche Palo Alto LLC
18539453 9 Identification of novel non-peptide CXCR4 antagonists by ligand-based design approach.EBI Kyoto University
17715128 6 Allosteric transinhibition by specific antagonists in CCR2/CXCR4 heterodimers.EBI Université Libre de Bruxelles
17599916 6 Molecular mechanism of action of monocyclam versus bicyclam non-peptide antagonists in the CXCR4 chemokine receptor.EBI University of Copenhagen
17958344 2 Discovery of small molecule CXCR4 antagonists.EBI Emory University
17228861 34 Structure-activity relationships of cyclic peptide-based chemokine receptor CXCR4 antagonists: disclosing the importance of side-chain and backbone functionalities.EBI Kyoto University
15857134 32 Identification of novel low molecular weight CXCR4 antagonists by structural tuning of cyclic tetrapeptide scaffolds.EBI Kyoto University
15658852 8 Stereoselective synthesis of [L-Arg-L/D-3-(2-naphthyl)alanine]-type (E)-alkene dipeptide isosteres and its application to the synthesis and biological evaluation of pseudopeptide analogues of the CXCR4 antagonist FC131.EBI Kyoto University
11958995 9 Synthesis and evaluation of pseudopeptide analogues of a specific CXCR4 inhibitor, T140: the insertion of an (E)-alkene dipeptide isostere into the betaII'-turn moiety.EBI Kyoto University
11720852 51 Design, synthesis, and SAR of heterocycle-containing antagonists of the human CCR5 receptor for the treatment of HIV-1 infection.EBI Merck Research Laboratories
11720851 52 Discovery of human CCR5 antagonists containing hydantoins for the treatment of HIV-1 infection.EBI Merck Research Laboratories